Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if milnacipran taken twice daily is effective in reduction of headache pain.


Clinical Trial Description

Milnacipran is a serotonin norepinephrine reubtake inhibitor (SNRI) approved for the management of fibromyalgia in the United States. Migraine and fibromyalgia have significant co-morbidity. Of 100 patients with fibromyalgia, 76% had chronic headaches, of whom 63% had migraine. Interestingly, general measures of pain, disability, sleep quality, and psychological distress were similar in individuals with fibromyalgia with and without headache. Conversely, the prevalence of fibromyalgia in women with migraine was reported as 22%, and at a headache referral center, 36% of headache patients had fibromyalgia. Because of significant co-morbidity, as well as the likelihood of shared pathophysiologic mechanisms, there is reason to believe that a medication effective for fibromyalgia might reduce migraine pain, especially where the pain has taken on the nature of a chronic pain disorder, as in chronic migraine. The current study evaluated the benefits of milnacipran in individuals with chronic migraine. Patients with chronic migraine were randomized to either Milnacipran or Placebo. Patients completed 30 days of baseline followed by 90 days of headache diaries while taking assigned medication. Primary outcomes were reduction in pain severity and improvement in migraine specific quality of life (MSQ) while secondary outcomes included reduction in migraine and non-migraine headache days and symptomatic use of medication for migraine. Independent sample t-tests were used to evaluate the changes in primary and secondary measures between the two groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01393522
Study type Interventional
Source Mercy Research
Contact
Status Completed
Phase N/A
Start date June 2011
Completion date December 2013

See also
  Status Clinical Trial Phase
Completed NCT05720819 - Biofeedback-VR for Treatment of Chronic Migraine N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Completed NCT02514148 - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients N/A
Enrolling by invitation NCT02291380 - A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine Phase 3
Withdrawn NCT02122744 - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine N/A
Completed NCT02122237 - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial Phase 3
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01709708 - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine Phase 4
Completed NCT01741246 - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging N/A
Completed NCT01090050 - Treximet in the Treatment of Chronic Migraine Phase 4
Recruiting NCT03507400 - Introvision for Migraine and Headaches N/A
Completed NCT04161807 - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine N/A
Completed NCT03175263 - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT01700387 - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency Phase 4
Completed NCT01667250 - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine N/A
Not yet recruiting NCT01135784 - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache Phase 2
Completed NCT00772031 - NINDS CRC Chronic Migraine Treatment Trial Phase 3